← Leaderboards
Andrew S Kraft
University Of Colorado Denver
$21,224,247
Attributed
$21,306,138
Total exposure
49
Grants
39
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.3M · FY2005–23$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$51,894,584 · 52
By mechanism
P30$42,403,435 · 36
R01$4,213,695 · 5
U54$1,703,102 · 1
T32$832,947 · 1
P20$774,465 · 1
R21$669,996 · 2
Top collaborators
- Margaret M Briehl3 shared
- Michael B Lilly1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- James V Degregori$21,700,379
- Elizabeth J Shpall$12,617,686
- Douglas K Graham$6,579,169
- Nina S Kadan-Lottick$5,510,109
- David A. Norris$7,265,873
Others in their field
Top investigators on “Universities”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$507,483,583
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$463,124,587
- Mitchell J Malone · Texas A&M Research Foundation$353,400,900
Research focus
UniversitiesCancer CenterCancer Center Support GrantProgramsMedicalMalignant NeoplasmsSouth CarolinaFundingResource SharingResearch PersonnelLeadershipMemberBaseResourcesMissionClinical ResearchClinical TrialsTranslational ResearchAreaCollegeGrowthStrategic PlanningCollaborationsEnsure
Grant awards (195)
Regulation of RNA Decapping and Degradation: A novel approach to prostate cancer therapy$397,168
R43 · FY2023 · CA · contact PI
Addressing Breast Cancer Health Disparities in American Indians through Translational and Dissemination/Implementation Science$170,497
U54 · FY2020 · CA
2/2 Partnership for Native American Cancer Prevention$166,201
U54 · FY2020 · CA
2/2 Partnership for Native American Cancer Prevention$1,366,404
U54 · FY2019 · CA
University of Arizona Cancer Center - Cancer Center Support Grant$3,533,423
P30 · FY2018 · CA · contact PI
Administration$894,982
P30 · FY2018 · CA · contact PI
Developmental Funds$311,324
P30 · FY2018 · CA · contact PI
University of Arizona Cancer Center - Cancer Center Support Grant$300,000
P30 · FY2018 · CA · contact PI
University of Arizona Cancer Center - Cancer Center Support Grant$249,999
P30 · FY2018 · CA · contact PI
University of Arizona Cancer Center - Cancer Center Support Grant$200,000
P30 · FY2018 · CA · contact PI
University of Arizona Cancer Center - Cancer Center Support Grant$112,000
P30 · FY2018 · CA · contact PI
Planning & Evaluation$61,160
P30 · FY2018 · CA · contact PI
Administration$16,667
P30 · FY2018 · CA · contact PI
Planning & Evaluation$16,667
P30 · FY2018 · CA · contact PI
Developmental Funds$16,666
P30 · FY2018 · CA · contact PI
Administration$13,890
P30 · FY2018 · CA · contact PI
Planning & Evaluation$13,888
P30 · FY2018 · CA · contact PI
Developmental Funds$13,888
P30 · FY2018 · CA · contact PI
Administration$11,112
P30 · FY2018 · CA · contact PI
Developmental Funds$11,110
P30 · FY2018 · CA · contact PI
Planning & Evaluation$11,110
P30 · FY2018 · CA · contact PI
CANCER CONTROL$9,254
P30 · FY2018 · CA · contact PI
Leaders of Scientific Research Programs$9,254
P30 · FY2018 · CA · contact PI
CANCER GENES & MOLECULAR REGULATION$9,254
P30 · FY2018 · CA · contact PI
CANCER IMMUNOLOGY$9,254
P30 · FY2018 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM$9,254
P30 · FY2018 · CA · contact PI
CELL EVALUATION & THERAPY$9,254
P30 · FY2018 · CA · contact PI
Clinical Trials Office and Data & Safety Monitoring$9,254
P30 · FY2018 · CA · contact PI
BIOSTATISTICS SHARED RESOURCE GROUP$9,254
P30 · FY2018 · CA · contact PI
CELL AND MOLECULAR IMAGING$9,254
P30 · FY2018 · CA · contact PI
LIPIDOMICS SHARED RESOURCE GROUP$9,254
P30 · FY2018 · CA · contact PI
DEVELOPMENTAL CANCER THERAPEUTICS$9,254
P30 · FY2018 · CA · contact PI
BIOREPOSITORY & TISSUE ANALYSIS$9,254
P30 · FY2018 · CA · contact PI
Administration$9,254
P30 · FY2018 · CA · contact PI
Developmental Funds$9,254
P30 · FY2018 · CA · contact PI
Planning and Evaluation$9,254
P30 · FY2018 · CA · contact PI
Senior Leadership$9,254
P30 · FY2018 · CA · contact PI
INCLUSION OF CHILDREN IN CLINICAL RESEARCH$9,253
P30 · FY2018 · CA · contact PI
INCLUSION OF MINORITIES IN CLINICAL RESEARCH$9,253
P30 · FY2018 · CA · contact PI
INCLUSION OF WOMEN IN CLINICAL RESEARCH$9,253
P30 · FY2018 · CA · contact PI
Center Director$9,253
P30 · FY2018 · CA · contact PI
Institutional Commitment$9,253
P30 · FY2018 · CA · contact PI
Cancer Focus$9,253
P30 · FY2018 · CA · contact PI
Transdisciplinary Collaboration and Coordination$9,253
P30 · FY2018 · CA · contact PI
OVERALL IMPACT/PRIORITY SCORE$9,252
P30 · FY2018 · CA · contact PI
NIH POLICY ON SHARING OF MODEL ORGANISMS$9,252
P30 · FY2018 · CA · contact PI
CRITERION SCORING$9,252
P30 · FY2018 · CA · contact PI
DURATION$9,252
P30 · FY2018 · CA · contact PI
Administration$6,223
P30 · FY2018 · CA · contact PI
Planning & Evaluation$6,221
P30 · FY2018 · CA · contact PI
Developmental Funds$6,221
P30 · FY2018 · CA · contact PI
University of Arizona Cancer Center - Cancer Center Support Grant$3,533,423
P30 · FY2017 · CA · contact PI
Administration$1,021,019
P30 · FY2017 · CA · contact PI
Developmental Funds$344,734
P30 · FY2017 · CA · contact PI
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors$318,513
R01 · FY2017 · CA · contact PI
University of Arizona Cancer Center - Cancer Center Support Grant$75,000
P30 · FY2017 · CA · contact PI
Planning & Evaluation$21,903
P30 · FY2017 · CA · contact PI
University of Arizona Cancer Center - Cancer Center Support Grant$3,533,423
P30 · FY2016 · CA · contact PI
Administration$955,024
P30 · FY2016 · CA · contact PI
University of Arizona Cancer Center - Cancer Center Support Grant$744,675
P30 · FY2016 · CA · contact PI
Senior Leadership$384,491
P30 · FY2016 · CA · contact PI
Developmental Funds$326,360
P30 · FY2016 · CA · contact PI
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors$318,513
R01 · FY2016 · CA · contact PI
Developmental Funds$307,791
P30 · FY2016 · CA · contact PI
Clinical Trials Office and Data & Safety Monitoring$184,725
P30 · FY2016 · CA · contact PI
Administration$180,697
P30 · FY2016 · CA · contact PI
Leaders of Scientific Research Programs$172,221
P30 · FY2016 · CA · contact PI
BIOSTATISTICS SHARED RESOURCE GROUP$170,468
P30 · FY2016 · CA · contact PI
Pim 1 Protein Kinase in Regulating Stromal Cell Biology in Prostate Cancer$166,886
R21 · FY2016 · CA · contact PI
University of Arizona Cancer Center - Cancer Center Support Grant$125,000
P30 · FY2016 · CA · contact PI
LIPIDOMICS SHARED RESOURCE GROUP$113,933
P30 · FY2016 · CA · contact PI
CELL AND MOLECULAR IMAGING$101,640
P30 · FY2016 · CA · contact PI
BIOREPOSITORY & TISSUE ANALYSIS$93,109
P30 · FY2016 · CA · contact PI
CELL EVALUATION & THERAPY$90,564
P30 · FY2016 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM$67,900
P30 · FY2016 · CA · contact PI
Planning & Evaluation$57,627
P30 · FY2016 · CA · contact PI
DEVELOPMENTAL CANCER THERAPEUTICS$43,057
P30 · FY2016 · CA · contact PI
CANCER GENES & MOLECULAR REGULATION$43,057
P30 · FY2016 · CA · contact PI
CANCER IMMUNOLOGY$43,056
P30 · FY2016 · CA · contact PI
CANCER CONTROL$43,056
P30 · FY2016 · CA · contact PI
Planning and Evaluation$34,666
P30 · FY2016 · CA · contact PI
Arizona Cancer Center-Cancer Center Support Grant$1,917,600
P30 · FY2015 · CA · contact PI
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors$311,097
R01 · FY2015 · CA · contact PI
Senior Leadership$274,637
P30 · FY2015 · CA · contact PI
Developmental Funds$233,115
P30 · FY2015 · CA · contact PI
Pim 1 Protein Kinase in Regulating Stromal Cell Biology in Prostate Cancer$199,610
R21 · FY2015 · CA · contact PI
Clinical Trials Office and Data & Safety Monitoring$131,947
P30 · FY2015 · CA · contact PI
Administration$129,070
P30 · FY2015 · CA · contact PI
Arizona Cancer Center-Cancer Center Support Grant$124,932
P30 · FY2015 · CA · contact PI
Leaders of Scientific Research Programs$123,014
P30 · FY2015 · CA · contact PI
BIOSTATISTICS SHARED RESOURCE GROUP$121,764
P30 · FY2015 · CA · contact PI
LIPIDOMICS SHARED RESOURCE GROUP$81,381
P30 · FY2015 · CA · contact PI
CELL AND MOLECULAR IMAGING$72,600
P30 · FY2015 · CA · contact PI
BIOREPOSITORY & TISSUE ANALYSIS$66,507
P30 · FY2015 · CA · contact PI
CELL EVALUATION & THERAPY$64,689
P30 · FY2015 · CA · contact PI
Arizona Cancer Center-Cancer Center Support Grant$50,000
P30 · FY2015 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM$48,501
P30 · FY2015 · CA · contact PI
DEVELOPMENTAL CANCER THERAPEUTICS$30,754
P30 · FY2015 · CA · contact PI
CANCER IMMUNOLOGY$30,753
P30 · FY2015 · CA · contact PI
CANCER GENES & MOLECULAR REGULATION$30,753
P30 · FY2015 · CA · contact PI
CANCER CONTROL$30,753
P30 · FY2015 · CA · contact PI
Planning and Evaluation$24,762
P30 · FY2015 · CA · contact PI
Senior Leadership$274,637
P30 · FY2014 · CA · contact PI
Developmental Funds$233,115
P30 · FY2014 · CA · contact PI
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors$228,635
R01 · FY2014 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$147,406
P30 · FY2014 · CA · contact PI
Clinical Trials Office and Data & Safety Monitoring$131,947
P30 · FY2014 · CA · contact PI
Administration$129,070
P30 · FY2014 · CA · contact PI
Leaders of Scientific Research Programs$123,014
P30 · FY2014 · CA · contact PI
BIOSTATISTICS SHARED RESOURCE GROUP$121,764
P30 · FY2014 · CA · contact PI
LIPIDOMICS SHARED RESOURCE GROUP$81,381
P30 · FY2014 · CA · contact PI
CELL AND MOLECULAR IMAGING$72,600
P30 · FY2014 · CA · contact PI
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors$72,272
R01 · FY2014 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$68,061
P30 · FY2014 · CA · contact PI
BIOREPOSITORY & TISSUE ANALYSIS$66,507
P30 · FY2014 · CA · contact PI
CELL EVALUATION & THERAPY$64,689
P30 · FY2014 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM$48,501
P30 · FY2014 · CA · contact PI
DEVELOPMENTAL CANCER THERAPEUTICS$30,754
P30 · FY2014 · CA · contact PI
CANCER CONTROL$30,753
P30 · FY2014 · CA · contact PI
CANCER GENES & MOLECULAR REGULATION$30,753
P30 · FY2014 · CA · contact PI
CANCER IMMUNOLOGY$30,753
P30 · FY2014 · CA · contact PI
Planning and Evaluation$24,762
P30 · FY2014 · CA · contact PI
Arizona Cancer Center-Cancer Center Support Grant$3,676,771
P30 · FY2013 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$1,310,169
P30 · FY2013 · CA · contact PI
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors$310,213
R01 · FY2013 · CA · contact PI
Senior Leadership$209,386
P30 · FY2013 · CA · contact PI
Developmental Funds$171,725
P30 · FY2013 · CA · contact PI
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan$163,782
K12 · FY2013 · CA · contact PI
Program Planning and Evaluation$73,722
P30 · FY2013 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$34,031
P30 · FY2013 · CA · contact PI
Developmental Funds$3,095
P30 · FY2013 · CA · contact PI
Senior Leadership$3,095
P30 · FY2013 · CA · contact PI
Program Planning and Evaluation$3,095
P30 · FY2013 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$1,401,250
P30 · FY2012 · CA · contact PI
Senior Leadership$328,001
P30 · FY2012 · CA · contact PI
Developmental Funds$244,314
P30 · FY2012 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$65,782
P30 · FY2012 · CA · contact PI
Senior Leadership$65,782
P30 · FY2012 · CA · contact PI
Program Planning and Evaluation$26,526
P30 · FY2012 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$1,401,250
P30 · FY2011 · CA · contact PI
Senior Leadership$351,931
P30 · FY2011 · CA · contact PI
Developmental Funds$262,136
P30 · FY2011 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$57,649
P30 · FY2011 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$50,000
P30 · FY2011 · CA · contact PI
Program Planning and Evaluation$28,458
P30 · FY2011 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$1,557,517
P30 · FY2010 · CA · contact PI
Senior Leadership$437,298
P30 · FY2010 · CA · contact PI
Developmental Funds$325,724
P30 · FY2010 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$95,580
P30 · FY2010 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$88,205
P30 · FY2010 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$84,727
P30 · FY2010 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$48,882
P30 · FY2010 · CA · contact PI
Program Planning and Evaluation$35,360
P30 · FY2010 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$2,548,679
P30 · FY2009 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$1,654,330
P30 · FY2009 · CA · contact PI
Senior Leadership$408,147
P30 · FY2009 · CA · contact PI
Developmental Funds$304,009
P30 · FY2009 · CA · contact PI
Novel Inhibitors of Pim Protein Kinases$257,864
R41 · FY2009 · CA · contact PI
Medical University of South Carolina - Cancer Center Support Grant$95,580
P30 · FY2009 · CA · contact PI
Program Planning and Evaluation$33,005
P30 · FY2009 · CA · contact PI
Mechanisms by which Proteasome Enhance Apoptosis$227,033
R01 · FY2007 · CA · contact PI
Mechanisms by which Proteasome Enhance Apoptosis$233,813
R01 · FY2006 · CA · contact PI
Hollings Cancer Center Planning Grant$250,000
P20 · FY2005 · CA
Mechanisms by which Proteasome Enhance Apoptosis$239,440
R01 · FY2005 · CA
Hollings Cancer Center Planning Grant$264,961
P20 · FY2004 · CA
Mechanisms by which Proteasome Enhance Apoptosis$239,440
R01 · FY2004 · CA
Mechanisms by which Proteasome Enhance Apoptosis$10,109
R01 · FY2004 · CA
Hollings Cancer Center Planning Grant$259,504
P20 · FY2003 · CA
CONTROL OF DIFFERENTIATION OF HUMAN PROMYELOCYTES$258,926
R01 · FY2003 · CA
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS$245,597
T32 · FY2003 · CA
Pim 1 protein kinase as a target for drug discovery$104,781
R21 · FY2003 · CA
Pim 1 protein kinase as a target for drug discovery$47,719
R21 · FY2003 · CA
CONTROL OF DIFFERENTIATION OF HUMAN PROMYELOCYTES$252,557
R01 · FY2002 · CA
DEVELOPMENTAL THERAPEUTICS PROGRAMS$250,404
P30 · FY2002 · CA
DEVELOPMENTAL THERAPEUTICS PROGRAMS$250,404
P30 · FY2002 · CA
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS$205,293
T32 · FY2002 · CA
PHASE II TRIAL OF BRYOSTATIN 1 FOR TREATMENT OF STAGE IV BREAST CANCER$190,747
M01 · FY2002 · RR
Pim 1 protein kinase as a target for drug discovery$151,000
R21 · FY2002 · CA
DEVELOPMENTAL THERAPEUTICS PROGRAMS$250,404
P30 · FY2001 · CA
CONTROL OF DIFFERENTIATION OF HUMAN PROMYELOCYTES$246,373
R01 · FY2001 · CA
REGULATION OF PROSTATE CANCER PROGRAMMED CELL DEATH$237,943
R01 · FY2001 · CA
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS$196,111
T32 · FY2001 · CA
PHASE II TRIAL OF BRYOSTATIN 1 FOR TREATMENT OF STAGE IV BREAST CANCER$190,747
M01 · FY2001 · RR
DEVELOPMENTAL THERAPEUTICS PROGRAMS$0
P30 · FY2001 · CA
PHASE II TRIAL OF BRYOSTATIN 1 FOR TREATMENT OF STAGE IV BREAST CANCER$0
M01 · FY2001 · RR
CONTROL OF DIFFERENTIATION OF HUMAN PROMYELOCYTES$240,366
R01 · FY2000 · CA
MECHANISM OF ACTION OF GM-CSF$235,703
R01 · FY2000 · DK
REGULATION OF PROSTATE CANCER PROGRAMMED CELL DEATH$232,749
R01 · FY2000 · CA
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS$185,946
T32 · FY2000 · CA
BRYOSTATIN 1 TREATMENT FOR PATIENTS WITH METASTATIC MALIGNANT MELANOMA$32,212
M01 · FY2000 · RR
PHASE II TRIAL OF BRYOSTATIN 1 FOR TREATMENT OF STAGE IV BREAST CANCER$32,212
M01 · FY2000 · RR
PHASE I/II RX OF CHRONIC MYELOGENOUS LEUKEMIA WITH BRYOSTATIN 1$32,212
M01 · FY2000 · RR
PHASE I/II RX OF CHRONIC MYELOGENOUS LEUKEMIA WITH BRYOSTATIN 1$0
M01 · FY2000 · RR
PHASE II TRIAL OF BRYOSTATIN 1 FOR TREATMENT OF STAGE IV BREAST CANCER$0
M01 · FY2000 · RR
BRYOSTATIN 1 TREATMENT FOR PATIENTS WITH METASTATIC MALIGNANT MELANOMA$0
M01 · FY2000 · RR